Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1995-10-18
|
pubmed:abstractText |
To evaluate the prognostic significance and clinicopathologic correlation of proliferative activity in patients with hepatocellular carcinoma, Ki-67 antigen expression was examined using immunohistochemical staining with monoclonal antibody MIB1. Seventy-two patients (65 men, 7 women; age range 24-77 years, mean, 52 years) having hepatocellular carcinoma surgically resected were studied. Tumor and nontumorous tissues were stained with monoclonal antibody MIB1 with microwave oven pretreatment. Tumor and nontumor MIB1 (T-MIB1 and NT-MIB1) scores were assessed by counting the positive staining nuclei per 1,000 cells. The T-MIB1 score ranged from 5-630 per 1,000 cells (mean +/- standard deviation [SD] = 145 +/- 162). It was found to be significantly higher in less well-differentiated tumors (Edmondson's grades III and IV) than in well-differentiated ones (Edmondson's grades I and II) (P = .017). The T-MIB1 score was also higher in nonencapsulated tumors than in encapsulated ones, although it did not reach statistical significance (P = .069). It had no influence on tumor size, tumor invasiveness, the background disease in the nontumorous livers, patients' HBsAg status, or serum alpha-fetoprotein levels. Diseases in the nontumorous livers or patients' HBsAg status had no influence on the NT-MIB1 scores. When the tumors were stratified into two groups with T-MIB1 score < or = 20 and T-MIB1 score > 20, those patients with score < or = 20 had significantly longer disease-free survival (DFS) than those with scores > 20 (median DFS: 34 months and 4.7 months, respectively; P = .011). In addition, MIB1 and PCNA were closely correlated (P < .01). The authors conclude that proliferative activity in hepatocellular carcinoma, as defined by MIB1 immunohistochemical analysis, is significantly related to tumor cellular differentiation. It is also a potentially valuable prognostic factor in patients with this tumor.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Ki-67 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proliferating Cell Nuclear Antigen
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0002-9173
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
104
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
313-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7545866-Adult,
pubmed-meshheading:7545866-Aged,
pubmed-meshheading:7545866-Antibodies, Monoclonal,
pubmed-meshheading:7545866-Carcinoma, Hepatocellular,
pubmed-meshheading:7545866-Female,
pubmed-meshheading:7545866-Humans,
pubmed-meshheading:7545866-Immunohistochemistry,
pubmed-meshheading:7545866-Ki-67 Antigen,
pubmed-meshheading:7545866-Liver Neoplasms,
pubmed-meshheading:7545866-Male,
pubmed-meshheading:7545866-Middle Aged,
pubmed-meshheading:7545866-Neoplasm Proteins,
pubmed-meshheading:7545866-Nuclear Proteins,
pubmed-meshheading:7545866-Prognosis,
pubmed-meshheading:7545866-Proliferating Cell Nuclear Antigen,
pubmed-meshheading:7545866-Staining and Labeling,
pubmed-meshheading:7545866-Survival Analysis
|
pubmed:year |
1995
|
pubmed:articleTitle |
Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1. A comparison with proliferating cell nuclear antigen.
|
pubmed:affiliation |
Department of Pathology, University of Hong Kong, Queen Mary Hospital, Pokfulam.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|